Form 4: Castle Bio CEO Sells Shares Under 10b5-1 Plan

Castle Biosciences CEO Derek J. Maetzold sold 1,339 shares of common stock for $22.58 per share under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Derek J. Maetzold, President & Chief Executive Officer and Director of Castle Biosciences Inc. (CSTL), reported a sale of common stock.
• The transaction involved 1,339 shares of common stock.
• The shares were sold on October 2, 2025, at a weighted-average price of $22.58 per share, with individual trades ranging from $22.31 to $23.14.
• The sale was executed pursuant to a Rule 10b5-1 plan adopted by Mr. Maetzold on May 8, 2025.
• Following this transaction, Mr. Maetzold directly beneficially owns 64,327 shares of common stock.
• Mr. Maetzold also indirectly beneficially owns 216,454 shares through various trusts, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, several Maetzold 2018 Remainder Trusts, and DJM Grantor Retained Annuity Trusts No. 5, 6, and 7.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider stock sale under a Rule 10b5-1 plan, which is generally considered neutral and not indicative of significant positive or negative sentiment regarding the company's prospects.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned and systematic approach to stock sales rather than an opportunistic one based on new material information.

Negatives

• An insider sale, even if pre-planned, reduces the direct ownership stake of a key executive.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• "These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025."
• "The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."

Industry Context

This is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive landscape.

Related Party Transactions

• The filing details indirect beneficial ownership through various trusts (e.g., The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, DJM Grantor Retained Annuity Trusts) where the reporting person or their family members are trustees or beneficiaries. These entities are considered related parties.

Stakeholder Impact

• Minimal impact on shareholders due to the small number of shares sold and the pre-planned nature of the transaction, which suggests it is not based on new material information.

Key Dates

Recommendation

This Form 4 reports a small, pre-planned insider sale under a 10b5-1 plan. Such routine transactions typically do not signal a change in the company's fundamental outlook or warrant a shift in investment strategy. Without additional information, a 'hold' recommendation is appropriate as this filing alone does not provide sufficient grounds for a 'buy' or 'sell' decision.

Keywords

Castle Biosciences, CSTL, Derek Maetzold, CEO, Director, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Equity Transaction